In vivo studies demonstrated that DPPA-RRPNP@Fe2O3 treatment significantly reduced tumor surface PD-L1 expression (Fig. 13c) and enhanced T-cell activation compared to RRPNP@Fe2O3 controls (Fig. 13d, e). This evidence concerns the gene CD274 and neoplasm.